Showing 161 - 180 results of 111,681 for search '(( significant ((gap decrease) OR (a decrease)) ) OR ( significant association analyses ))', query time: 4.36s Refine Results
  1. 161
  2. 162
  3. 163
  4. 164
  5. 165
  6. 166
  7. 167
  8. 168
  9. 169
  10. 170

    Table_1_A novel defined m7G regulator signature to investigate the association between molecular characterization and clinical significance in lung adenocarcinoma.xlsx by Yi Dong (440404)

    Published 2022
    “…</p>Results<p>Compared to the low-risk group, the high-risk group had a decreased overall survival (OS) (P=0.047). The risk score and stage were independent factors for predicting the OS of LUAD (P=0.0004 and P<0.0001, respectively). …”
  11. 171

    Voxel based analyses for fractional anisotropy (FA) and apparent diffusion coefficient (ADC) detected increased FA and decreased ADC in trained reachers relative to controls. by Alexandra Badea (352052)

    Published 2019
    “…Results are presented as <i>t</i>maps, FDR cluster-corrected for multiple comparisons using an initial cluster forming threshold of 0.05 significance, and the whole brain as a mask. Uncorrected statistical maps are also shown in yellow, suggesting microstructural changes in the hippocampus and isocortex.…”
  12. 172
  13. 173
  14. 174
  15. 175
  16. 176
  17. 177
  18. 178
  19. 179

    Factors associated with TB recurrence after completing TB treatment as a single outcome or part of a composite outcome (Gap 5). by Tulip A. Jhaveri (18625800)

    Published 2024
    “…Only statistically significant findings are presented. Some studies in the review with adjusted analyses reported nonsignificant findings for sex [<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1004409#pmed.1004409.ref081" target="_blank">81</a>,<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1004409#pmed.1004409.ref111" target="_blank">111</a>], medication adherence [<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1004409#pmed.1004409.ref081" target="_blank">81</a>,<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1004409#pmed.1004409.ref106" target="_blank">106</a>], undernutrition [<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1004409#pmed.1004409.ref106" target="_blank">106</a>], and smoking [<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1004409#pmed.1004409.ref106" target="_blank">106</a>,<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1004409#pmed.1004409.ref111" target="_blank">111</a>]. …”
  20. 180

    Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58 by Avivit Cahn (10072991)

    Published 2022
    “…Dapagliflozin led to a decrease in the risk of CVD/HHF, HHF and the cardiorenal outcome vs. placebo with no heterogeneity by baseline HbA1c (P-interaction >0.05).…”